{
    "root": "2f273079-119d-75f6-e063-6394a90abb25",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Meloxicam",
    "value": "20250227",
    "ingredients": [
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "LACTOSE",
            "code": "J2B2A4N98G"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "SODIUM CITRATE",
            "code": "1Q73Q2JULR"
        },
        {
            "name": "MELOXICAM",
            "code": "VG2QF83CGL"
        }
    ],
    "indications": "meloxicam non-steroidal anti-inflammatory indicated : osteoarthritis ( oa ) ( 1.1 ) rheumatoid arthritis ( rheumatoid arthritis ) ( 1.2 ) juvenile rheumatoid arthritis ( jra ) patients weigh ≥60 kg ( 1.3 )",
    "contraindications": "lowest effective shortest duration consistent individual patient treatment goals . ( 2.1 ) . oa ( 2.2 ) rheumatoid arthritis ( 2.3 ) : ​​ - starting dose : 7.5 mg daily - dose may increased 15 mg daily jra ( 2.4 ) : - 7.5 mg daily children ≥60 kg meloxicam tablets , usp interchangeable approved formulations oral meloxicam even total milligram strength ( 2.6 )",
    "warningsAndPrecautions": "meloxicam tablets available pastel yellow , round , biconvex , uncoated tablets containing meloxicam 7.5 mg. 7.5 mg tablet impressed “ 5 ” mark one side . meloxicam tablets , usp 7.5 mg available follows : ndc 43063-395-14 ; bottles 14 ndc 43063-395-20 ; bottles 20 ndc 43063-395-60 ; bottles 60 ndc 43063-395-90 ; bottles 90 ndc 43063-395-95 ; bottles 1000 storage store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . dispense tablets tight container . keep medications reach children . keep meloxicam tablets dry place .",
    "adverseReactions": "meloxicam contraindicated following patients : known hypersensitivity ( e.g . , anaphylactic serious skin ) meloxicam components product [ ( 5.7 , 5.9 ) ] history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients [ ( 5.7 , 5.8 ) ] setting coronary artery bypass graft ( cabg ) surgery [ ( 5.1 ) ]",
    "indications_original": "Meloxicam is a non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) ( 1.1 ) Rheumatoid Arthritis (RA) ( 1.2 ) Juvenile Rheumatoid Arthritis (JRA) in patients who weigh ≥60 kg ( 1.3 )",
    "contraindications_original": "Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. ( 2.1 ). OA ( 2.2 ) and RA ( 2.3 ):​​ - Starting dose: 7.5 mg once daily - Dose may be increased to 15 mg once daily JRA ( 2.4 ): - 7.5 mg once daily in children ≥60 kg Meloxicam Tablets, USP are not interchangeable with approved formulations of oral meloxicam even if the total milligram strength is the same ( 2.6 )",
    "warningsAndPrecautions_original": "Meloxicam Tablets are available as pastel yellow, round, biconvex, uncoated tablets containing meloxicam 7.5 mg. The 7.5 mg tablet is impressed with “5” mark on one side.\n                  \n                  Meloxicam Tablets, USP 7.5 mg is available as follows:\n  \nNDC 43063-395-14; Bottles of 14\n  \nNDC 43063-395-20; Bottles of 20\n  \nNDC 43063-395-60; Bottles of 60\n  \nNDC 43063-395-90; Bottles of 90\n  \nNDC 43063-395-95; Bottles of 1000\n \n                  \n                  \n                     Storage\n                     \nStore at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].\n  \nDispense tablets in a tight container.\n  \nKeep this and all medications out of the reach of children.\n  \nKeep Meloxicam Tablets in a dry place.",
    "adverseReactions_original": "Meloxicam is contraindicated in the following patients:\n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to meloxicam or any components of the drug product\n  \n   [see Warnings and Precautions (\n                        5.7\n                        ,\n                        5.9\n                        )]\n \n  \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [\n  \n   see Warnings and Precautions (\n                        5.7\n                        ,\n                        5.8\n                        )]\n \n  \n                     In the setting of coronary artery bypass graft (CABG) surgery [\n  \n   see Warnings and Precautions (\n                        5.1\n                        )]"
}